510(k) Report

510(k) · Cleared

Cleared

FreeStyle Libre 2 Flash Glucose Monitoring System

K211102510(k) TraditionalCleared Aug 11, 2021120-day reviewClass II21 CFR 862.1355

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Abbott Diabetes Care, Inc. · QLG Integrated Continuous Glucose Monitoring System, Factory Calibrated, Not For Use With Automated Insulin Delivery Systems

Cleared on Aug 11, 2021 as substantially equivalent to K193371 (Abbott Diabetes Care, Inc., 2020) after a 120-day review. Its family tree reaches back 2 generations to 2018. 1 of the 3 devices in its family, counting itself, has a Class I recall.

Decided
Aug 11, 2021
Review
120 days
Class
Class II
Product code
QLG
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to DEN170088 (2018). No later device cites it as a predicate yet. 1 of the 3 devices in this family, counting this one, has a Class I recall.

  1. Root · 2 generations backDEN170088 Dexcom G6 Continuous Glucose Monitoring SystemDexcom, Inc. · 2018
  2. 1 generation backK193371 FreeStyle Libre 2 Flash Glucose Monitoring SystemAbbott Diabetes Care, Inc. · 2020 · Recalled (Class I)
  3. This deviceK211102 FreeStyle Libre 2 Flash Glucose Monitoring SystemAbbott Diabetes Care, Inc. · 2021

Class I recalls in this family

View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2DEN170088Dexcom G6 Continuous Glucose Monitoring SystemDexcom, Inc.2018—
−1K193371FreeStyle Libre 2 Flash Glucose Monitoring SystemAbbott Diabetes Care, Inc.2020Class I
0 (this device)K211102FreeStyle Libre 2 Flash Glucose Monitoring SystemAbbott Diabetes Care, Inc.2021—
FIG. 1 — Lineage of K211102, 2018–2021Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

1 device in this family has a Class I recall. A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new QLG device

  1. #1 K210943 FreeStyle Libre 2 Flash Glucose Monitoring…score 12.0 · 3 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K193371FreeStyle Libre 2 Flash Glucose Monitoring System
Summary page 4
…Clinical Chemistry 1.3 Predicate Device Predicate Device: FreeStyle Libre 2 Flash Glucose Monitoring System (K193371, cleared on June 12, 2020) This predicate device has not been subject to a recall…
Abbott Diabetes Care, Inc.2020Class I

Also cleared against K193371: 2 other devices →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (1 Class I)

No FDA recall names this device.

Relatives with a Class I recall

Class I is FDA’s most serious recall class. A recall in the family tree is context for this device, not evidence about it.

  • K193371FreeStyle Libre 2 Flash Glucose Monitoring SystemAbbott Diabetes Care, Inc. · 2020 · Direct predicate · ◆ on the line of descent in FIG. 11 Class I recall

What does this lineage say?

  • The line of descent spans 3 years and passes through 2 companies; a new generation was cleared every 2.2 years on median.
  • 1 of the 2 ancestors has a recall of any class; 1 has a Class I recall.
  • 2 other devices also cite its predicate K193371.

How does its category compare?

All QLG devices

QLG Integrated Continuous Glucose Monitoring System, Factory Calibrated, Not For Use With Automated Insulin Delivery Systems: FDA decisions, review times, recalls and adverse event reports over 20 years. 2021, this device’s year, is highlighted.

FDA decisions per year · QLG

2in 2023

2020: 12021: 42022: 22023: 2
2007high 4 (2021) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · QLG

259in 2021

2021: 259 days median
2007high 259 (2021)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · QLG

4in 2025

2023: 12025: 4, 4 Class I
2007high 4 (2025) · low 0 (2007)2026

Class I (4 since 2007) Class II/III not classified

Adverse event reports per year · QLG

20,199in 2025

2020: 1,0692021: 22,5002022: 26,5282023: 39,3212024: 35,1082025: 20,199
2007high 39,321 (2023) · low 0 (2007)2025

MAUDE reports naming product code QLG, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20180—00
20190—00
20201—01,069
20214259022,500
20222—026,528
20232—139,321
20240—035,108
20250—4 (4)20,199
20260—0—

What is it indicated for?

The FreeStyle Libre 2 Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device with real time alarms capability indicated for the management of diabetes in persons age 4 and older. It is intended to replace blood glucose testing for diabetes treatment decisions, unless otherwise indicated. The System also detects trends and tracks patterns and aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both…

Read the full statement (148 words)

The FreeStyle Libre 2 Flash Glucose Monitoring System is a continuous glucose monitoring (CGM) device with real time alarms capability indicated for the management of diabetes in persons age 4 and older. It is intended to replace blood glucose testing for diabetes treatment decisions, unless otherwise indicated.

The System also detects trends and tracks patterns and aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating both acute and long-term therapy adjustments. Interpretation of the System readings should be based on the glucose trends and several sequential readings over time.

The System is also intended to autonomously communicate with digitally connected devices. The System can be used alone or in conjunction with these digitally connected devices where the user manually controls actions for therapy decisions.

The System can be used with the FreeStyle Libre 2 Sensor (14 day) or the FreeStyle Libre 2 MediRx Sensor (10 day).

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K211102: FreeStyle Libre 2 Flash Glucose Monitoring System.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K211102

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026